CBL antibody

GeneTex

CBL antibody

9

WB: 0.5 - 2 microg/mL. IHC-P: 20 microg/mL. *Optimal dilutions/concentrations should be determined by the researcher.Not tested in other applications.

Western Blot, ELISA, ImmunoHistoChemistry, ImmunoHistoChemistry Paraffin

Research Use Only

Polyclonal

1 mg/ml

Unconjugated

CBL

Cbl proto-oncogene

Cas-Br-M (murine) ecotropic retroviral transforming sequence; casitas B-lineage lymphoma proto-oncogene; Cbl proto-oncogene, E3 ubiquitin protein ligase; CBL2; C-CBL; E3 ubiquitin-protein ligase CBL; FRA11B; fragile site, folic acid type, rare, fra(11)(q23.3); NSLL; oncogene CBL2; proto-oncogene c-Cbl; RING finger protein 55; RING-type E3 ubiquitin transferase CBL; RNF55; signal transduction protein CBL

Rabbit

IgG

E3 ubiquitin-protein ligase CBL

This gene is a proto-oncogene that encodes a RING finger E3 ubiquitin ligase. The encoded protein is one of the enzymes required for targeting substrates for degradation by the proteasome. This protein mediates the transfer of ubiquitin from ubiquitin conjugating enzymes (E2) to specific substrates. This protein also contains an N-terminal phosphotyrosine binding domain that allows it to interact with numerous tyrosine-phosphorylated substrates and target them for proteasome degradation. As such it functions as a negative regulator of many signal transduction pathways. This gene has been found to be mutated or translocated in many cancers including acute myeloid leukaemia. Mutations in this gene are also the cause of Noonan syndrome-like disorder. [provided by RefSeq, Mar 2012]

Human, Mouse, Rat

-20°C or -80°C,2°C to 8°C

12352203